Skip to main content

Table 5 Characteristics of anti-CCP-positive and -negative PsA patients

From: Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis

 

Anti-CCP-positive

(n = 7)

Anti-CCP-negative

(n = 33)

P-value

Age (years)

   

Mean ± SD (range)

43 ± 5.7 (39–50)

47 ± 6.9 (33–54)

0.161*

Sex

   

Male n (%)

3 (42.86%)

15 (45.45%)

 

female n (%)

4 (57.14%)

18 (54.55%)

0.67**

Disease Duration (months)

   

Mean ± SD (range)

40.7 ± 12.34 (30–54)

37 ± 9 (24–60)

0.36*

PASI

   

Mean ± SD (range)

10 ± 1.53 (8–11)

8.86 ± 1.9 (7–13)

0.146*

Psoriatic nail changes

   

n (%)

4 (57.14%)

29 (87.9%)

0.087**

Involved joints

   

median (range)

15 (10–24)

6 (5–10)

0.0135*

Swollen joints

   

median (range)

2.5 (2–7)

1 (0–2)

0.023*

Tender joints

   

median (range)

9 (3–16)

3 (0–8)

0.009*

Spondyloarthritis

   

n (%)

1 (14.28%)

5 (15.15%)

0.901**

Oligoarthritis

   

n (%)

0

6 (18.18%)

0.567**

Symmetric Polyarthritis

   

n (%)

7 (100%)

12 (36.36%)

0.003**

Asymmetric Polyarthritis

   

n (%)

0

2 (6.06%)

0.542**

Deformities of peripheral joints

   

n (%)

7 (100%)

15 (45.45%)

0.011**

Functional impairment of peripheral joints

   

n (%)

7 (100%)

15 (45.45%)

0.011**

Radiological changes:

peripheral deformities/erosions

   

n (%)

7 (100%)

15 (45.45%)

0.011**

RF concentrations (IU/ml)

   

Median (range)

15 (7–30)

9 (4–33)

0.0714*

Anti-CCP concentrations (U/ml)

Mean ± SD (range)

34.7 ± 8 (30–45)

3.21 ± 1.16 (1–5)

0.0001*

  1. * Student's t and Mann Whitney tests.
  2. ** Chi-square and Fisher's exact tests